Tiplaxtinin inhibits plasminogen activator inhibitor 1 (PAI-1), decreasing would closure and collagen deposition. Tiplaxtinin exhibits anti-inflammatory, anti-fibrotic, anti-allergic, anti-angiogenic, and anticancer chemotherapeutic activities. Tiplaxtinin inhibits carotid artery neointimal formation and increases apoptosis in vascular smooth muscle cells. In models of bladder cancer, this compound inhibits angiogenesis, increases apoptosis, and decreases cell proliferation, cell adhesion, and tumor growth. Tixplatinin also decreases inflammation, collagen deposition, and airway hyperresponsiveness in animal models of OVA-induced pulmonary remodeling.